Skip to content
CompoundSci
All peptides
Research vial labelled Lipo-C, a Fat loss and metabolic peptide studied in preclinical and clinical literature

Lipo-C

Methionine, inositol, choline blend

The file here is mostly preclinical work plus clinic and community practice, not registrational trials.

A lipotropic vitamin blend, not a peptide. Controlled evidence for fat loss is essentially absent.

General profile

Class
Fat loss and metabolic
Evidence
Early or preclinical only
Studied dose range
0.5–1 mL of the compounded blend
Frequency in protocols
1–2× weekly
Route
Intramuscular in clinic protocols
Half life
Component dependent
Reconstitution
Supplied as a solution
Storage
Refrigerated, light-protected

Timing and cycling in the literature

Usually dosed in the morning window

One to two times weekly

A compounded vitamin blend given intramuscularly in clinic settings. Morning dosing is convention, not pharmacology.

Reported cycle: 8 weeks on, 4 weeks off

Clinic protocols run weekly injections in blocks alongside a diet phase, not indefinitely.

Watch for: Injection site soreness and B-vitamin flushing.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

  • Pick oneRedundant, pick one

    Lipo-C + AOD-9604

    Same target hit twice

    Overlapping fat-metabolism framing with no additive evidence.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how Lipo-C fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: No completed human efficacy trial that establishes a dose for the use people are chasing.

Open questions: Treat published dosing as observed practice, not a validated protocol.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Search the full literature